Trivarx Limited · ASX:TRI
Trivarx — TechKnow Invest Roadshow July 2024
19 slides from Trivarx's conference presentation, Jul 30, 2024
Slide 1: ASX Announcement: TechKnow Invest Roadshow presentation
ASX ANNOUNCEMENT 30 July 2024 TechKnow Invest Roadshow presentation Perth, Australia, and Minneapolis, USA: TrivarX Limited (‘the Company’) (ASX: TRI) is pleased to advise that Chief Operating Officer, Mr Kai Sun will be presenting at the TechKnow Invest Roadshow event in Sydney and Melbourne on 30
Slide 2: AI-driven solutions to objectively screen for mental health conditions
For personal use only AI-driven solutions to objectively screen for mental health conditions TECHKNOW INVEST ROADSHOW – JULY 2024 (ASX: TRI) This presentation has been authorised for release by the Board of TrivarX Limited
Slide 3: Forward looking statements
Forward looking statements The purpose of the presentation is to provide an update of the business of TrivarX Limited (ASX: TRI). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slide
Slide 4: Corporate overview, board and management, major shareholders
Corporate overview Non-Executive Chairman Mr David Trimboli Board and management ASX code: TRI Chief Operating Officer Mr Kai Sun Corporate Snapshot Executive Director Dr Tony Keating Shares on issue: ~457m For personal use only Non-Executive Director Mr Chris Ntoumenopoulos Market capitalisation (a
Slide 5: Company overview
Company overview Pioneering the use of AI to aid in the early detection of mental health conditions AI-driven, scientifically-backed software tools to objectively screen mental health conditions For personal use only Lead program, MEB-001 uses biometric data, EEG and ECG recordings collected during
Slide 6: The US mental health epidemic
The US mental health epidemic 21% of US adults experience mental illness – the equivalent to over 50m Americansᶦ 1 in 25 US adults live with a serious mental health For personal use only condition such as major depression, bipolar and schizophreniaᶦᶦ 55% of US adults with a mental health condition r
Slide 7: Sleep and mental health are deeply intertwined
Sleep and mental health are deeply intertwined TrivarX is exploring the robust relationship between sleep and mental health using AI Depression and sleep problems are closely linked: For personal use only ⚬ People with insomnia may have a tenfold higher risk of developing depression than people who
Slide 8: A scientifically backed approach
A scientifically backed approach Underpinned by leading management, extensive experience and industry validation Leading scientific expertise Extensive industry validation For personal use only Archie Defillo M.D. – Chief Medical Officer 25 years clinical experience with neurological diseases and a
Slide 9: AI used to connect proprietary sleep biomarkers with mental health
AI used to connect proprietary sleep biomarkers with mental health Large training dataset of sleep studies and For personal use only matching mental health assessments AI model training to identify specific Extraction of over 60 mental health proprietary indication biomarkers of mental Identificatio
Slide 10: An enviable global database
An enviable global database Leveraging the world’s largest repositories of EEG and ECG data combined with neuropsychiatric evaluations Over 1,000 unique For personal use only patient cases collected 1,000+ PHQ9s completed by patients Over 400 MINIs Used by clinicians in structured interviews to find
Slide 11: MEB-001, lead product targets the major market of depression
MEB-001, TrivarX’s lead product targets the major market of depression For personal use only Kaiser Permanente estimates that doctors miss 50% of depression cases in the USᶦ Only 1.4% of US outpatients are screened for depression at the primary care levelᶦᶦ Depression screening is not part of clinic
Slide 12: MEB-001 is the only objective depression screening tool for sleep centres
MEB-001 is the only objective depression screening tool for sleep centres For personal use only Clinical and regulatory development MEB-001 is TRI’s AI-driven algorithm which well progressed assists in the screening of depression TrivarX’s first proprietary algorithm, MEB-001, is being developed as
Slide 13: Positive outcome in MEB-001 Phase trial
Positive outcome in MEB-001 Phase 2 trial Summary Study Sleep Signal Analysis for Current Major Depressive Episode (SAMDE) – NCT0570822 For personal use only Use MEB-001 to detect likelihood of a current Major Depressive Episode (cMDE) using Clinician Reporting Outcomes (CRO) Objective assessment in
Slide 14: The start of a large global opportunity in mental health
The start of a large global opportunity in mental health Trivarx is positioned to be the world leader in AI-based assessment of mental health Expanding Indications Reaching more patients For personal use only In clinic sleep labs Depression At home sleep testing Anxiety Opioid use disorder Bipolar d
Slide 15: Multiple near-term value catalysts
Multiple near-term value catalysts Catalyst Timeframe (CY) Status Second FDA Pre-Submission Meeting H1 2024 ✔ Completion of MEB-001 SAMDE Phase 2 Trial H1 2024 ✔ For personal use only Final data from MEB-001 SAMDE Phase 2 Trial H2 2024 ✔ Appointments to strengthen Board of Directors H2 2024 ✔ Commen
Slide 16: Contact
For personal use only CONTACT TrivarX Limited (ASX: TRI) E: Investors@trivarx.com A: 647 Beaufort Street, Mt Lawley, WA 6050 Kai Sun – Chief Operating Officer: T: +61 433 549 602 E: Kai.sun@trivarx.com Henry Jordan – Six Degrees Investor Relations T: +61 431 271 538 E: Henry.Jordan@sdir.com.au 15
Slide 17: Appendix 1: Intellectual Property and patents
Appendix 1: Intellectual Property and patents Four patents granted and currently active For personal use only US Pat. No. 10,912,508 US Pat. No. 10,638,965 Issued 09 Feb 2021 Issued 05 May 2020 Method and system for assessing Method and system for monitoring mental state stress conditions US Pat. No
Slide 18: Appendix 2: Clinical research and technology
Appendix 2: Clinical Clinical Study SLEEP SADB SAMDE PI SAMDE PII Clinical Validation research and technology Status Complete Complete Complete Complete Planned SEEG SEEG SEEG Software SEEG SEEG Supervised Artificial Intelligence Module(s) SHRV SHRV SHRV DMI SHRV DMI SHRV DMI For personal use only L
Slide 19: Appendix 3: MEB-001 Hypnogram outputs
Appendix 3: MEB-001 Hypnogram outputs cMDE Negative cMDE Positive For personal use only TechKnow Invest Roadshow - July 2024 18